Calderón-Jaimes E, Espinosa MLE, Avila-Beltrán R

Idioma: Ingles.
Referencias bibliográficas: 23
Paginas: 108-112
Archivo PDF: 40.06 Kb.

RESUMEN

Objetivo. Determinar la frecuencia de la resistencia a la meticilina y la actividad de varios antibióticos. Material y métodos. Se incluyeron 1 209 cepas de Staphylococcus spp. procedentes de pacientes del Instituto Nacional de Pediatría y del Hospital Infantil de México Federico Gómez. Se utilizó la técnica de dilución en placas con agar. El procedimiento e interpretación fueron acordes con lo establecido por el National Committee for Clinical Laboratory Standards. Resultados. La frecuencia de la resistencia de S. aureus fue de 14.2% y de 53.4% en los Staphylococcus coagulasa negativa. La actividad de otros antimicrobianos se presenta en el texto. Conclusiones. Es necesario vigilar continuamente la progresión de la resistencia de Staphylococcus spp. a la meticilina.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Lowy FD. Staphylococcus aureus infection. N Engl J Med 1998;320: 520-532.

2. Crossley KB, Archer GL, ed. The staphylococci in human diseases. Nueva York: Churchill Livingstone, 1997.

3. Archer GL. Staphylococcus aureus: A well-armed pathogen. Clin Infect Dis 1998;26:1179-1181.

4. Conterno LO, Wey SB, Castelo A. Risk factors for mortality in Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 1998;19:32-37.

5. Romero-Vivas J, Rubio M, Fernández C, Picazo JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1995;21:1417-1423.

6. Musher OM, Lamm N, Daroniche RO, Young EJ, Hamill RJ, Landon GC. The current spectrum of Staphylococcus aureus infection in a tertiary care hospital. Medicine (Baltimore) 1994;73:186-208.

7. Bone RC. Gram-positive organisms and sepsis. Arch Intern Med 1994;154:26-34.

8. Witte W. Antibiotic resistance in gram-positive bacteria: Epidemiologic aspects. J Antimicrob Chemother 1999;44 (Suppl A): 1-9.

9. Kloos WE, Bannerman TL. Update on clinical significance of coagulasenegative staphylococci. Clin Microbial Rev 1994;7:117-140.

10. Viagappan N, Kelsey MC. The origin of coagulase-negative staphylococci isolated from blood cultures. J Hosp Infect 1995;30:217-223.

11. Raad L, Alrahwan A, Rolston K. Staphylococcus epidermidis: Emerging resistance and need for alternative agents. Clin Infect Dis 1998; 26:1182-1187.

12. Rupp ME, Archer GL. Coagulase-negative staphylococci: Pathogens associated with medical progress. Clin Infect Dis 1994;19:231-243.

13. Waldvogel FA. New resistance in Staphylococcus aureus. N Engl J Med 1999;340:556-557.

14. Chambers HF. Methicillin resistance in staphylococci. Molecular and biochemical basis and clinical implications. Clin Microbiol Rev 1997;10: 781-791.

15. Pfaller MA, Jones RN, Doern GV, Sader HS, Kugler KC, Beach ML et al. Survey of bloodstream infections due to gram-positive cocci: Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America for the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 1999;33:283-297.

16. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl Med 1987;316: 927-931.

17. Kloos WK, Bannerman TL. Staphylococcus and Micrococcus. En: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, ed. Manual of clinical microbiology. 7th ed. Washington, D.C.: ASM Press, 1999: 264-282.

18. National Committee for Clinical Laboratory Standards. Antimicrobial susceptibility test for bacteria that grow aerobically: Approved Standard. 5th ed. Wayne (PA): National Committee for Clinical Laboratory Standards, 2000; NCCLS document M7-A5.

19. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: Tenth informational supplement Wayne (PA): National Committee for Clinical Laboratory Standards. 2000; M100-S10.

20. Emory TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6: 428-442.

21. Fridkin SK, Steward CD, Edwards JR, Pryor EE, Mc Gowan JE, Archivald LK et al. Surveillance of antimicrobial use and antimicrobial resistance in the United States hospitals: Project ICARE phase 2. Clin Infect Dis 1999; 29: 245-252.

22. Brumfitt W, Hamilton-Miller JM, Shah S. In vitro activity of RP59500 a new semisynthetic antibiotic, against gram-positive bacteria. J Antimicrob Chemother 1992; 30 (Suppl A):27-37.

23. Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM et al. Randomized comparison of Linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44: 3408-4813.